Dry Eye

Laura Periman, MD, talks through what was gained from the conference, from becoming acquainted with new technological advancements to renewing passion for dry eye care.

The transient receptor potential melastatin 8 (TRPM8) are cold-sensitive thermoreceptors that play central role in tear film homeostasis.

Marc R Bloomenstein, OD, FAAO, chats with Optometry Times on the benefits of using Vevye to treat dry eye disease, when to prescribe, and how to distinguish quality candidates.

R Tracy Williams, OD, FAAO, has been team optometrist for the Chicago Bulls and White Sox for over 20 years. He details how treatment of professional athletes is different than the general public in an exclusive interview with Optometry Times.

Education, together with strong recommendations, in-office retail, habit hacks, and follow-up visits, supports patient compliance.

Phase 3 of the randomized, double-masked, placebo-controlled study had a primary end point to evaluate the signs and symptoms of dry eye disease caused by Sjögren syndrome.

By targeting tear evaporation, F6H8 ushers in a new era of dry eye treatment.

Harrow’s Vevye is the first and only cyclosporine-based product approved for the treatment of both signs and symptoms of dry eye disease.

AR-15512 is a topical transient receptor potential melastatin 8 (TRPM8) agonist designed to treat the signs and symptoms of DED via increased tear production.

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

Dry eye disease incidence rates vary markedly depending on the eye care practice.

Vezocolmitide is the first drug candidate based on PolyCol, Stuart Therapeutics' patented synthesized polypeptide collagen mimetic peptide platform.

A look back at some of the biggest stories in ophthalmology in 2023.

Dr Amy Nau outlines her comprehensive strategy for addressing Demodex infestations and explains how she combines therapies to manage multifactorial dry eye disease.

Amy Nau, OD, discusses a challenging case of Demodex infestation in a 32-year-old male suffering from severe anxiety due to Rosacea and Demodex.

Amy Nau, DO, presents another case of Demodex in a female patient, highlighting the multifaceted approach required for successful treatment.

Dr Amy Nau shares a patient case involving a female with Demodex infestation, ultimately treated with lotilaner.

Kelly K. Nichols, OD, MPH, PhD, FAAO, and A. Paul Chous, OD, FAAO, recap the diverse topics at EyeCon 2023, emphasizing the collaborative spirit between optometrists and ophthalmologists in addressing issues such as myopia management, diabetic eye conditions, cataract surgery, and patient referrals.

According to the company, an additional trial is required to show positive effects on the treatment of ocular symptoms in dry eye disease.

2 cases illustrate the importance of ocular surface optimization.

Using the NEI protocol for addressing corneal staining, researchers used 5 microliters of 2%, non preserved fluorescein and then evaluated corneal staining.

By taking a proactive approach to treatment, identify the “silent sufferers.”

According to Sun Pharmaceutical Industries, the study design mirrors real-world experience with dry eye disease, including allowing use of artificial tears and measurement of CFS in all 5 corneal zones.

The FDA recalled 26 eye drops due to risk of infection and possible vision loss.